SCHEMBL11575

SCHEMBL11575

CCC(C(N)=O)c1ccc(-c2ccc3c(c2)C(=O)NC3)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.53
NTRK2 Q16620 2/20 0.53
DYRK1B Q9Y463 2/20 0.53
TYRO3 Q06418 1/20 0.53
NTRK1 P04629 2/20 0.52
FLT3 P36888 2/20 0.52
GSK3B P49841 2/20 0.52
JAK2 O60674 1/20 0.52
MET P08581 1/20 0.52
FGFR1 P11362 1/20 0.52
PRKACA P17612 1/20 0.52
KDR P35968 1/20 0.52
MAP2K2 P36507 1/20 0.52
MAP2K1 Q02750 1/20 0.52
MST1R Q04912 1/20 0.52
NTRK3 Q16288 1/20 0.52
CAMK1D Q8IU85 1/20 0.52
FYN P06241 1/20 0.49
LIPC P11150 2/20 0.39
PRMT5 O14744 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5998 0.90 PRF1 (0.48) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL8193675 0.73 CLK4 (0.47) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL11574 0.72 NTRK2 (0.56) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL29985572 0.72 CLK4 (0.74) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL19187116 0.72 CLK4 (0.74) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL8166417 0.72 CLK4 (0.46) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL8723086 0.71 CLK4 (1.00) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL11898716 0.71 TP53 (0.58) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL8813871 0.70 FFAR1 (0.44) ROCK1
SCHEMBL21731307 0.70 CLK4 (0.73) CLK4NTRK2DYRK1BTYRO3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-12-11 US disclosed
US-8853258-B2 C-linked hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-10-07 US disclosed
EP-2488489-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc. (US) 2012-08-22 EP disclosed
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents BROWN MATTHEW FRANK (US) 2012-08-09 US disclosed
WO-2011045703-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents HAX1, LPXN, AGXT CLK4 3296/4885NTRK2 4633/4885DYRK1B 3582/4885
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents LCT, AGXT, PRXL2A CLK4 2560/4885NTRK2 4794/4885DYRK1B 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.